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Essential tremor (ET) is a neurologic disease
that is characterized by an action tremor of
the hands and/or head. Patients also may have
signs of more widespread cerebellar involve-
ment (e.g., intention tremor, ataxia; Deuschl
et al. 2000; Singer et al. 1994; Stolze et al.
2000), abnormalities referable to the basal
ganglia (e.g., rest tremor, subclinical signs of
bradykinesia; Cohen et al. 2003; Rajput et al.
1993), and cognitive deﬁcits (Gasparini et al.
2001; Lombardi et al. 2001). ET is considered
to be distinct from age-related enhanced phys-
iologic tremor, which has different clinical
and electrophysiologic features (Louis et al.
1997; Louis and Pullman 2001). The disease
is highly prevalent in the general population
(1–6%) (Louis et al. 1998b; Rautakorpi et al.
1982) and occurs in all populations studied to
date (Hornabrook and Nagurney 1976; Louis
et al. 1998b). The prevalence increases with
age. Estimates of the prevalence in individuals
who are in their sixties and seventies have
been as high as 20.5% (Khatter et al. 1996).
As such, ET is one of the most common neu-
rologic diseases. The pathogenesis of this pro-
gressive (Louis et al. 2003) and often disabling
(Louis et al. 2001a) disease is poorly under-
stood, although there is evidence of cerebellar
involvement (Bucher et al. 1997; Louis et al.
2002a; Wills et al. 1994). There is no cure for
ET, and there has been no attempt to favor-
ably modulate or halt its progression with
neuroprotective therapy. Medical treatment
merely aims to lessen the severity of the
tremor, which is the major symptom, and the
ﬁrst-line medications are ineffective in up to
50% of patients (Gironell et al. 1999; Louis
and Greene 2000; Sasso et al. 1990).
Although genetic susceptibility is an
important determinant of disease etiology
(Louis et al. 2001b; Tanner et al. 2001), it has
been hypothesized that nongenetic factors
(i.e., environmental factors such as toxicants)
could contribute to disease etiology in many
cases (Louis 2001; Louis et al. 2002b; Tanner
et al. 2001). The identiﬁcation of these factors
is a critical step in disease prevention, yet they
have received little attention (Louis 2001).
Lead is a ubiquitous toxicant (Konat and
Clausen 1974; Schroeder and Tipton 1968),
and laboratory animals and humans exposed to
high levels of either inorganic or organic forms
of lead develop neurologic disorders in which
action tremor is prominent (Booze et al. 1983;
Coulehan et al. 1983; Goldings and Stewart
1982; Konat and Clausen 1974; Seshia et al.
1978; Valpey et al. 1978; Young et al. 1977).
Destruction of cerebellar Purkinje cells is a
major feature of the pathology of lead toxicity
(Valpey et al. 1978). The effect of chronic,
low-level exposure to lead has been linked with
developmental problems, deﬁcits in intellectual
performance and decreased stature in children
(Brody et al. 1994), and poorer performance
on cognitive tests in adults (Muldoon et al.
1993; Payton et al. 1998).
To test the hypothesis that ET is associ-
ated with lead exposure (Louis 2001), we
assessed a) blood lead (BPb) concentrations
and b) lifetime occupational history in ET
patients and in control subjects who were
enrolled in a study of the environmental
epidemiology of ET.
Materials and Methods
Participants. ET patients were cared for by
neurologists at the Neurological Institute of
New York, Columbia-Presbyterian Medical
Center (CPMC) (Louis et al. 2002b). They
were identiﬁed from a computerized database
listing patients billed within the last 3 years
supplemented by a computerized database at
the Center for Parkinson’s Disease and Other
Movement Disorders, CPMC, which listed
patients seen within the last 10 years. All
patients had received a diagnosis of ET from
their treating neurologist at the institute. ET
patients were selected for enrollment in a
study of the environmental epidemiology of
ET. Ofﬁce records were reviewed and patients
with physical signs or diagnoses of dystonia,
parkinsonism (rigidity, bradykinesia), or spin-
ocerebellar ataxia were excluded. The CPMC
internal review board approved of all study
procedures, and written informed consent was
obtained at the time of enrollment.
Controls were identified from the New
York metropolitan area using random-digit
dialing. These controls were frequency matched
to CPMC patients based on 5-year age strata,
sex, and ethnicity.
Patients and controls were contacted;
77.2% of patients and 57.0% of controls
agreed to participate. Enrollees were similar to
refusers in terms of age (68.0 ± 10.0 vs. 66.8 ±
16.7 years; mean ± SD), sex (54.7% vs.
54.2% female), race (90.1% vs. 86.1% white),
and education (14.7 ± 4.0 vs. 14.6 ± 3.6 years;
all p > 0.05).
Environmental Health Perspectives • VOLUME 111 | NUMBER 14 | November 2003 1707
Association between Essential Tremor and Blood Lead Concentration
Elan D. Louis,1,2,3 Eva C. Jurewicz,1 LaKeisha Applegate,1 Pam Factor-Litvak,4 Michael Parides,5 Leslie Andrews,6
Vesna Slavkovich,6 Joseph H. Graziano,6,7 Spencer Carroll,8 and Andrew Todd 8
1Gertrude H. Sergievsky Center, 2Taub Institute for Research on Alzheimer’s Disease and the Aging Brain, and 3Department of Neurology,
College of Physicians and Surgeons, Columbia University, New York, New York, USA; 4Department of Epidemiology, 5Department of
Biostatistics, and 6Department of Environmental Health Sciences, Mailman School of Public Health, Columbia University, New York, 
New York, USA; 7Department of Pharmacology, College of Physicians and Surgeons, Columbia University, New York, New York, USA;
8Department of Community and Preventative Medicine, The Mount Sinai School of Medicine, New York, New York, USA
Address correspondence to E.D. Louis, Unit 198,
Neurological Institute, 710 West 168th Street, New
York, NY 10032, USA. Telephone: (212) 305-3665.
Fax: (212) 305-1304. E-mail: EDL2@columbia.edu
This work was supported by R01 NS39422, P30
ES09089, and RR00645 (General Clinical Research
Center) from the National Institutes of Health.
The authors declare they have no conﬂict of interest.
Received 22 April 2003; accepted 3 July 2003.
Lead is a ubiquitous toxicant that causes tremor and cerebellar damage. Essential tremor (ET) is a
highly prevalent neurologic disease associated with cerebellar involvement. Although environmental
toxicants may play a role in ET etiology and their identiﬁcation is a critical step in disease preven-
tion, these toxicants have received little attention. Our objective was to test the hypothesis that ET
is associated with lead exposure. Therefore, blood lead (BPb) concentrations were measured and a
lifetime occupational history was assessed in ET patients and in controls. We frequency matched
100 ET patients and 143 controls on age, sex, and ethnicity. BPb concentrations were analyzed
using graphite furnace atomic absorption spectrophotometry. A lifetime occupational history was
reviewed by an industrial hygienist. BPb concentrations were higher in ET patients than in controls
(mean ± SD, 3.3 ± 2.4 and 2.6 ± 1.6 µg/dL, respectively; median, 2.7 and 2.3 µg/dL; p = 0.038).
In a logistic regression model, BPb concentration was associated with diagnosis [control vs. ET
patient, odds ratio (OR) per unit increase = 1.21; 95% conﬁdence interval (CI), 1.05–1.39; p =
0.007]. BPb concentration was associated with diagnosis (OR per unit increase = 1.19; 95% CI,
1.03–1.37; p = 0.02) after adjusting for potential confounders. Prevalence of lifetime occupational
lead exposure was similar in ET patients and controls. We report an association between BPb con-
centration and ET. Determining whether this association is due to increased exposure to lead or a
difference in lead kinetics in ET patients requires further investigation. Key words: epidemiology,
essential tremor, etiology, lead, occupational exposure. Environ Health Perspect 111:1707–1711
(2003). doi:10.1289/ehp.6404 available via http://dx.doi.org/ [Online 3 July 2003]
Research ArticleBefore enrollment, ET patients and con-
trols were screened for cognitive impairment
using the 10-min Telephone Interview for
Cognitive Status (Brandt et al. 1988). This
was done to minimize the enrollment of indi-
viduals with invalid occupational, dietary, and
smoking histories. Three individuals (one
patient and two controls) with cognitive
impairment (score < 30 of 41) were excluded.
Patients and controls were also screened by
telephone using a brief neurologic disease
questionnaire. This included one question
about each of the following conditions:
Parkinson’s disease, Alzheimer’s disease, dys-
tonia, epilepsy, and multiple sclerosis. They
were not enrolled if one of these conditions
was reported to be present.
Each patient and control had a videotaped
tremor examination, to which a diagnosis of
ET or normal was assigned. The diagnosis of
ET was based on published diagnostic criteria
(Louis et al. 2001b) that are unique in three
regards: a)t heir reliability has been demon-
strated (Louis et al. 1998a); b) they have been
validated against quantitative computerized
tremor analysis-derived diagnoses (Louis and
Pullman 2001); and c) these criteria were
speciﬁcally designed to minimize the inclusion
of individuals with enhanced physiologic
tremor, which is highly prevalent (Louis et al.
1997). They do so by specifying the number
and types of activities during which kinetic
tremor must be present in order to qualify for a
diagnosis of ET. In this regard, the criteria are
particularly useful for population-based, famil-
ial aggregation, and epidemiologic studies.
Demographic and medical history. Once
enrolled, all participants were evaluated in
person by a trained tester. The tester was
trained for 1 month by a neurologist (E.D.L.)
to administer clinical questionnaires and to
perform a videotaped examination. Data were
collected on age, sex, self-reported ethnicity,
socioeconomic variables (e.g., years of educa-
tion, number of rooms in home), and smok-
ing history (including current and past use of
cigarettes and pack-years). ET patients were
asked whether they had a ﬁrst-degree relative
with ET or with tremor. Patients who
responded afﬁrmatively to this question were
considered to have a family history of tremor.
Lifetime occupational history. The tester
also administered an in-person lifetime occupa-
tional history designed for the study by an
industrial hygienist (L. Andrews). The tester
was trained by the hygienist to administer this
history. To minimize reporting bias, study par-
ticipants were informed that this was a study of
living and working habits of people in the New
York metropolitan area rather than a study of
lead as a risk factor for ET. Information was
collected on all jobs held for ≥ 6 months,
including the name, location, and type of
employer(s), job titles and description of work
duties and tasks performed, and the time
period and duration of employment. For each
job for which a reasonable probability existed
for exposure to lead, there were detailed follow-
up questions about the work environment,
including the amount of time spent at that job,
type of ventilation, housekeeping and sanita-
tion practices, personal and protective equip-
ment used, and material handling procedures.
The industrial hygienist, unaware of
patient–control status, reviewed these data to
assess the possibility of lifetime occupational
exposure to lead. Final lifetime occupational
exposure status was coded as none, possible, or
probable. Possible lifetime occupational expo-
sure was defined as one of the following:
a) there was one or more job with a possible
association with lead, b) the participant identi-
ﬁed lead exposure, c) the participant described
work-site factors that the industrial hygienist
judged to be indicative of possible but not
conclusive exposure, or d) the participant
described work-site factors that the industrial
hygienist judged to be indicative of probable
occupational exposure only at minimal levels.
Probable lifetime occupational exposure was
the classification used when one or more of
the participant’s jobs were clearly associated
with lead or if the participant described work-
site factors that the industrial hygienist judged
to be indicative of probable and significant
exposure. In addition to lifetime exposure, the
industrial hygienist assessed whether the
exposure to lead was current.
Dietary assessment. Data on current diet
were collected using a semiquantitative food-
frequency questionnaire (Willett et al. 1985),
which included questions on frequency of
consumption of 61 foods and on the use of
vitamins and mineral supplements. Food fre-
quency data may be used to compute mean
daily intake of vitamins and minerals, includ-
ing vitamin C, calcium, and iron (in mil-
ligrams), each of which has been associated
with blood or bone lead concentrations
(Cheng et al. 1998; Dawson et al. 1999;
Hernandez-Avila et al. 1996; Willett 1990).
The questionnaire has shown good reliability
and validity related to recent nutrient intake
(Willett 1990; Willett et al. 1985). As in a
previous study of lead exposure (Hu et al.
1996), ethanol intake was stratiﬁed into two
groups: “heavy use” was deﬁned as ≥ 2 drinks
either of wine, beer, or spirits per day; “light
use” was deﬁned as < 2 drinks per day.
Videotaped examination. For all partici-
pants, the tester videotaped a tremor exami-
nation that included one test to elicit postural
tremor (sustained arm extension) and five
tests to elicit kinetic tremor (pouring, drink-
ing, using a spoon, touching finger to nose,
and drawing spirals) (Louis et al. 2001b).
Each of the six tests was performed with the
dominant arm and then the nondominant
arm (12 tests total) (Louis et al. 2001b). Each
videotape was reviewed by E.D.L., and the
tremor was rated during each of the 12 tests
on a scale of 0–3, which resulted in a total
tremor score [0–36 (maximum)]. The diag-
nosis of ET also was confirmed by E.D.L.
using published diagnostic criteria [moderate
or greater amplitude tremor (tremor rating
≥ 2) during three or more activities or a head
tremor] (Louis et al. 2001b).
BPb assessment. Venous blood samples
were collected in lead-free tubes and analyzed
using graphite furnace atomic absorption spec-
trophotometry (Perkin-Elmer Analyst 600;
Perkin Elmer, Chelmsford, MA) (Fernandez
and Hilligoss 1982) in the Trace Metal Core
Laboratory of the National Institute of
Environmental Health Science Center for
Environmental Health in Northern Manhattan
at Columbia University. These analyses were
performed blinded to clinical information.
The detection limit for BPb measurements
using these instruments was 0.1 µg/dL. Day-
to-day variability was 3.7%. The laboratory
participates in the BPb quality control program
of the Centers for Disease Control and
Prevention. The intraclass correlation coeffi-
cient, which quantiﬁes the association between
the measured and the quality control values for
BPb, was 0.99 during the course of this study.
Bone lead assessment. To assess whether
BPb concentrations were correlated with bone
lead concentrations, which reﬂect accumulated
exposure to lead (Todd and Chettle 1994),
bone lead concentrations were assessed at the
Mount Sinai School of Medicine (A.T. and
S.C.) in a subsample of 5–10% of participants
without current occupational lead exposure.
These participants were selected on the basis
of their proximity to the medical center. Tibia
lead was assessed via a 30-min measurement at
the left mid-tibial shaft using 109Cd-induced
K-shell X-ray ﬂuorescence (Todd et al. 2001a,
2001b, 2002), which yields a concentration in
units of micrograms of lead per gram of bone
mineral. Bone lead concentrations were not
assessed on the same day as BPb concentra-
tions, but were performed within 2 months of
one another.
Statistical analyses. Statistical analyses were
performed using SPSS software (version 11.0;
SPSS, Inc., Chicago, IL). BPb concentrations
were not normally distributed. Each analysis
was ﬁrst performed using log10 BPb and then
repeated using BPb. The results were similar.
Results were presented using BPb because non-
transformed data can be expressed in units of
micrograms per deciliter, which is a more easily
understandable unit of measure. When exam-
ining group differences in BPb concentration,
medians were compared using a nonparametric
approach (Mann-Whitney test). To assess asso-
ciations between BPb concentration and other
continuous variables (e.g., total tremor score)
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(r). To evaluate differences between categori-
cal variables [e.g., sex by diagnosis (ET patient
vs. control)], we used chi square tests. To
assess group differences in normally-distrib-
uted continuous variables (e.g., age), we used
the Student’s t-test.
Logistic regression analyses were per-
formed to test the association of BPb concen-
tration with diagnostic status (ET patient vs.
control). We began with an unadjusted model
and then considered variables that were sus-
pected to confound the lead–diagnosis associa-
tion or were known to be associated with BPb
(Cheng et al. 1998; Dawson et al. 1999;
Hernandez-Avila et al. 1996): age in years; sex;
race (white vs. nonwhite); number of rooms in
home; years of education; current cigarette
smoker (yes vs. no); pack-years of smoking;
reported daily consumptions of vitamin C,
calcium, and iron; and ethanol use (heavy vs.
light use). In the final model, we included a
variable if in a univariate model either a)i t
was associated with the diagnosis (at p < 0.10)
or b) it was associated with the BPb concentra-
tion (at p < 0.10). Because we did not want to
miss a potential association, we used a more
liberal criteria (p < 0.10) than typically used in
hypothesis testing.
Diagnosis by family history groups (con-
trol, ET patients with a family history of
tremor, ET patients without a family history
of tremor) were used to test the hypothesis
that ET patients without a family history of
tremor might have higher BPb concentrations
than controls. Multivariate logistic regression
analyses were performed to test the associa-
tion of BPb lead concentration with diagnosis
by family history group, using the same con-
founding variables used to model the associa-
tion of BPb concentration with ET diagnostic
status (ET patient vs. control).
We based sample size calculations on pilot
data collected from 20 controls. To detect a
25% increase in mean BPb concentrations in
patients, and assuming an α of 0.05, the
power with 100 participants in each group
was 84.7%, and with 150 participants in each
group was 95.5%. Control recruitment was
faster than that of ET patients, so that we
reached 143 controls at a point when we had
100 ET patients. The power to detect a 25%
difference with our sample (100 ET patients
and 143 controls) was 90.5%.
Results
There were 100 ET patients and 143 controls.
Patients were, on average, 4–5 years older than
controls but were otherwise similar (Table 1).
BPb concentrations and bone lead concentra-
tions in the 17 participants (10 patients and 7
controls) were correlated with one another
(Spearman’s r = 0.52, p = 0.03), suggesting
that individuals with higher current BPb levels
may have had higher lifetime exposures.
In controls, we assessed the associations
between BPb concentrations and possible con-
founding variables, including age, years of edu-
cation, number of rooms in home, number of
cigarette pack-years, and current reported con-
sumption (in milligrams per day) of vitamin C,
calcium, and iron (Table 2), but there were no
associations. In controls, BPb concentration
was higher in current cigarette smokers versus
nonsmokers (median, 3.5 µg/dL vs. 2.3 µg/dL;
Mann-Whitney z = 2.08; p = 0.038) but simi-
lar in males and females (median, 2.4 µg/dL vs.
2.2 µg/dL; Mann-Whitney z = 1.60; p = 0.11)
and in whites compared with nonwhites
(median, 2.3 µg/dL vs. 2.6 µg/dL; Mann-
Whitney z = 0.78; p = 0.43). In the eight con-
trols who were heavy ethanol users, the median
BPb concentration was 3.1 µg/dL compared
with 2.3 µg/dL in the 135 controls who were
light users (Mann-Whitney z = 0.97; p = 0.33).
The median BPb concentration was
2.7 µg/dL in ET patients versus 2.3 µg/dL in
controls (Mann-Whitney z = 2.08; p = 0.038).
The respective mean BPb concentrations
(± SD) were 3.3 ± 2.4 and 2.6 ± 1.6 µg/dL
(Figure 1). A BPb concentration > 10 µg/dL
was present in two (2%) ET patients and no
(0%) controls.
There was a correlation between the
total tremor score and BPb concentration
(Spearman’s r = 0.14; p = 0.03) in the 243
study subjects. In the ET patients, this correla-
tion was not signiﬁcant (Spearman’s r = 0.07;
p = 0.48; Figure 2). The 44 ET patients who
were taking medication for their tremor had
BPb concentrations that did not differ signiﬁ-
cantly from those of the 56 ET patients who
were not taking medication (median, 2.5 vs.
2.7 µg/dL, respectively; t = 1.26, p = 0.21).
In the unadjusted logistic regression model,
BPb concentration was associated with diagno-
sis [control vs. ET patient, odds ratio (OR) per
unit increase = 1.21; 95% conﬁdence interval
(CI), 1.05–1.39; p = 0.007]. The ﬁnal model
included BPb concentration as well as age and
current cigarette smoking status (yes vs. no). In
this model, the association between BPb con-
centration and diagnosis (OR per unit increase
= 1.19; 95% CI, 1.03–1.37; p = 0.02) was sim-
ilar to that obtained in the unadjusted model
(OR per unit increase = 1.21).
The BPb concentration was higher in the
39 ET patients without a family history of
tremor compared with the 61 ET patients
who had a family history (median, 3.0 µg/dL
vs. 2.4 µg/dL; Mann-Whitney z = 2.30;
p = 0.02). When ET patients without a family
history of tremor were compared with con-
trols, BPb concentrations differed (median,
3.0 µg/dL vs. 2.3 µg/dL; Mann-Whitney
z = 2.94; p = 0.003). In the unadjusted logistic
regression model, BPb concentration was asso-
ciated with diagnosis (control vs. ET patient
without a family history of tremor: OR per
unit increase = 1.40; 95% CI, 1.18–1.66;
p = 0.001). In the adjusted logistic regression
model, the association between BPb concen-
tration and diagnosis remained significant
(control vs. ET patient without a family his-
tory of tremor, OR per unit increase = 1.38;
95% CI, 1.15–1.64; p = 0.001).
Two percent of patients and 2% of con-
trols had current (possible or probable) occu-
pational lead exposure. Prevalence of lifetime
occupational lead exposure was similar in ET
patients and controls as well. Possible lifetime
occupational lead exposure occurred in 13
(13%) ET patients and 19 (13.3%) controls,
and probable lifetime occupational lead
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Table 1. ET patients versus control subjects.
ET patients (n = 100) Controls (n = 143)
Age (years) 70.7 ± 9.9* 66.2 ± 9.7
Sex (female) 54 (54) 79 (55.2)
Race (white) 91 (91) 129 (89.5)
Education (years) 14.2 ± 4.7 15.1 ± 3.3
Rooms in home 5.4 ± 2.3 6.0 ± 2.4
Current cigarette smoker 8 (8) 14 (9.8)
Cigarette pack-years 7.4 ± 18.8 9.8 ± 21.3
Vitamin C (mg/day)a 444.1 ± 386.2 432.8 ± 398.9
Calcium (mg/day)a 973.4 ± 590.7 935.5 ± 563.8
Iron (mg/day)a 14.7 ± 8.4 16.4 ± 13.1
≥ 2 alcoholic drinks/daya 10 (10.0) 8 (5.6)
Values shown are either mean ± SD or number (percent).
aReported current daily intake based on the semiquantitative food frequency questionnaire. *p < 0.001.
Table 2. Association between BPb concentration
and other variables.
Correlation with
BPb concentration
Age (years) r = 0.009, p = 0.91
Education (years) r = –0.005, p = 0.95
No. of rooms in home r = –0.003, p = 0.98
No. of cigarette pack-years r = –0.04, p = 0.64
Current reported consumptiona
Vitamin C (mg/day) r = –0.11, p = 0.21
Calcium (mg/day) r = –0.10, p = 0.25
Iron (mg/day) r = –0.13, p = 0.12
All r values are Spearman’s r. 
aReported current daily intake based on the semiquantitative
food frequency questionnaire.exposure occurred in 15 (15%) ET patients
and 15 (10.5%) controls (χ2 = 1.11; p = 0.57).
The prevalence of lifetime occupational expo-
sure to lead did not differ between ET patients
without a family history of tremor and con-
trols. There were 62 participants with possible
or probable lifetime occupational lead expo-
sure. Their BPb concentration was higher
than that of the 181 participants without this
exposure (median, 3.1 µg/dL vs. 2.4 µg/dL;
Mann-Whitney z = 2.91; p = 0.004). In a
logistic regression model, BPb concentration
was associated with diagnosis (control vs. ET
patient, OR per unit increase = 1.18; 95% CI,
1.03–1.37; p = 0.02) after adjusting for age,
current cigarette smoking status (yes vs. no),
and possible or probable lifetime occupational
lead exposure.
Discussion
In this case–control study, we found that the
BPb concentration was higher in ET patients
than in controls. This association between
higher BPb concentration and the diagnosis
of ET persisted after adjusting for confound-
ing variables. The association was strongest in
patients with sporadic ET, that is, those with
no family history of tremor, suggesting that
lead as a toxicant might be of more relevance
in ET patients without a genetic susceptibility
for ET. The prevalence of lifetime occupa-
tional exposure to lead was similar in ET
patients and controls, suggesting that the
higher BPb concentration in ET patients was
not due to increased risk of occupational
exposure. However, the prevalence of occupa-
tional lead exposure was very low in our study
population; thus, we cannot definitively
exclude occupational lead exposure as a risk
factor for ET.
Although the BPb concentration differed
between ET patients and controls, the con-
centration in our study participants was low,
reﬂecting the national decline in BPb concen-
trations since the removal of lead from gaso-
line and paint (Brody et al. 1994). BPb
concentrations in our population may have
been higher in the past. BPb concentrations
<1 0µ g/dL were previously thought to be safe;
however, they have been associated with neu-
rologic problems in children and adults (Brody
et al. 1994), suggesting that there are neuro-
logic sequelae of low levels of lead exposure. In
a report of 141 men taking part in a normative
aging study (Payton et al. 1998), mean BPb
concentrations were 5.5 µg/dL, and higher
concentrations of blood and bone lead were
associated with poorer performance on cogni-
tive tests. In 530 women 65–87 years of age
who were participants in a study of osteoporotic
fractures, BPb concentrations > 8 µg/dL were
associated with poorer performance on tests of
memory, visual perception, psychomotor speed,
manual dexterity, attention, and mental ﬂexibil-
ity (Muldoon et al. 1993).
Although our data demonstrate an associ-
ation between ET and higher BPb concentra-
tions, one must be cautious about the
interpretation of these data. It is unlikely that
a BPb concentration of 3.3 µg/dL alone is
sufficient to cause ET. If this were so, the
prevalence of ET might be higher than 1–6%.
An incidence study is needed to directly
address the issue of whether higher BPb con-
centrations precede or follow the diagnosis of
ET. Second, a study of bone lead concentra-
tion is required because this is a better mea-
sure of cumulative exposure to lead than are
BPb concentrations. These types of studies
are needed before a chelation trial, to try to
modify the subsequent progression of the dis-
ease (i.e., worsening of tremor) among ET
cases, should be considered.
Humans may be exposed to both inorganic
and organic forms of lead from occupational
and nonoccupational sources (Coulehan et al.
1983; Winegar et al. 1997). In humans and
rats, lead exposure may lead to acute and
chronic progressive disorders in which action
tremor is a prominent feature (Booze et al.
1983; Coulehan et al. 1983; Goldings and
Stewart 1982; Seshia et al. 1978; Valpey et al.
1978; Young et al. 1977). There is also evi-
dence that lead toxicity causes cerebellar
pathology. Rat pups fed a diet containing 4%
lead acetate demonstrated changes in the
topology of Purkinje cell dendritic trees due
to a change in Purkinje cell metabolism
(McConnell and Berry 1979). Perinatal expo-
sure to inorganic lead results in degenerative
changes in Purkinje cells in the rabbit cerebel-
lum (Walsh and Tilson 1984). Inorganic lead
exposure causes a reduction in the total num-
ber of cerebellar cells in developing rat brains
(Michaelson 1973). Moreover, an autopsy
study of humans with chronic organic lead
exposure revealed severe destruction of cerebel-
lar Purkinje cells (Valpey et al. 1978). Multiple
lines of evidence suggest that the cerebellum is
involved in ET, including imaging studies
[positron emission tomography (Wills et al.
1994), functional magnetic resonance imaging
(Bucher et al. 1997), and magnetic resonance
spectroscopic imaging (Louis et al. 2002a)],
clinical studies and electrophysiologic studies
(Deuschl et al. 2000; Gironell et al. 2000;
Stolze et al. 2000), and case reports (Dupuis et
al. 1989). Unfortunately, there have been few
postmortem studies of ET; several studies
revealed loss of cerebellar Purkinje cells, but
without control brains for comparison, these
results are difﬁcult to interpret (Louis 2001).
One limitation of the present study is its
cross-sectional rather than longitudinal design.
We did not study incident patients with ET.
The data do not directly address the issue of
whether higher BPb concentrations preceded
or followed the diagnosis of ET. Prospective
studies are needed to further assess the associa-
tions we reported in this study. Second, we
assessed BPb concentrations. Bone lead con-
centrations are a better measure of cumulative
exposure to lead, although there is a correla-
tion between the two in “steady-state” expo-
sure (Cheng et al. 1998). We performed bone
lead assessments on a subsample of ET
patients and controls and demonstrated a cor-
relation between the two measures, as has been
reported in several other studies of nonoccu-
pationally exposed (Cheng et al. 1998; Farias
et al. 1998; Kosnett et al. 1994) and occupa-
tionally exposed cohorts in steady-state expo-
sure (Börjesson et al. 1997). Sole use of BPb as
a measure of lead exposure might not have
optimized our ability to detect an association
between lead exposure and ET, thereby result-
ing in conservative estimates of this associa-
tion. In addition, in this study, ET patients
were asked whether they had a ﬁrst-degree rel-
ative with tremor. Patients who responded
afﬁrmatively to this question were considered
to have a family history of tremor. It is possi-
ble that this approach resulted in an overesti-
mation of the genetic component of ET and
that individuals without a genetic predisposi-
tion for tremor were included as individuals
with a family history of tremor. This would
have resulted in our having derived lower (i.e.,
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Figure 2. BPb concentration versus total tremor
score in ET patients. The regression line is also
shown.
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Figure 1. BPb concentration (µg/dL) in ET patients
and controls. The central box represents the mean,
and the bars represent 2× SE.conservative) estimates of the association
between BPb concentration and familial ET.
Despite these limitations, this is the ﬁrst study
to test the hypothesis that lead exposure may
be associated with ET. We therefore deem this
positive association to be potentially very
important.
In summary, we report an association
between BPb concentration and ET. Whether
this association is due to increased exposure to
lead or a difference in lead kinetics in ET
patients requires further investigation.
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